COVID-19Data ExclusivitiesTrade Policy Promotion of TRIPS-Plus Intellectual Property Provisions Through the Special 301 Review: How Did It Change During the COVID-19 Pandemic?August 17, 2021 This post introduces my chapter the Special 301 Report in the newly-published book Intellectual Property…Michael Palmedo COVID-19TRIPS COVID-19 Should Change the U.S. Posture on Global Access to MedicationMay 18, 2020 The U.S. has long deferred to pharmaceutical companies on questions of pricing and availability of…Michael PalmedoSrividhya Ragavan Search Search Blog Front Page CategoriesCategories Select Category COVID-19 (20) Data Exclusivities (5) Deceptive Claims (1) Exhaustion (2) Experimental Use (1) IPAB (1) Patent Pools (2) Patents (15) Right to Health (1) TAMU (1) Trade Policy (2) TRIPS (19) TRIPS Flexibilities (3) Vaccines (4) Voluntary Licenses (1) Archives Archives Select Month September 2021 August 2021 July 2021 May 2021 February 2021 January 2021 December 2020 October 2020 September 2020 August 2020 July 2020 June 2020 May 2020 Regular Contributors Doris Estelle Long (13) Srividhya Ragavan (9) Shirin Syed (2) Michael Palmedo (2) Jonathan Kimball (1) Sonal Singh (1) All Authors RECENT POSTS The Overlooked Role of Copyright in Securing Vaccine Distribution Equity WEBINAR: Accelerating the Global Vaccine Roll-Out Against COVID-19: Legal, Production and Logistical Measures Promotion of TRIPS-Plus Intellectual Property Provisions Through the Special 301 Review: How Did It Change During the COVID-19 Pandemic? Intellectual Property Law and Access to Medicines: TRIPS Agreement, Health and Pharmaceuticals India’s Vaccination Policy and the Covid-19 Second Wave: Lessons for the World
COVID-19TRIPS COVID-19 Should Change the U.S. Posture on Global Access to MedicationMay 18, 2020 The U.S. has long deferred to pharmaceutical companies on questions of pricing and availability of…Michael PalmedoSrividhya Ragavan
